Sales and Marketing

Showing 15 posts of 11524 posts found.

Janssen reaches partial agreement over criminal investigation

August 10, 2011 Sales and Marketing Janssen, Risperdal, US, US Justice Department, illegal

Janssen Pharmaceuticals has reached a partial agreement with the US government over a criminal investigation into the marketing of Risperdal. …

New MS drug shows promise for Abbott

August 10, 2011 Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya

Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …
Lord Howe

Taskforce to tackle £300m in wasted medicines

August 9, 2011 Sales and Marketing Lord Howe, NHS, medinces management

A task force has been set up to tackle medicine wastage in the NHS – a problem which, the government …

Pfizer teams up with University of California for drug discovery

August 9, 2011 Research and Development, Sales and Marketing Pfizer, academic research

Pfizer has signed a deal with the University of California to help expand its drug discovery and development programme. The …

Pradaxa approved for stroke prevention in Europe

August 9, 2011 Sales and Marketing Pradaxa, atrial fibrillation, direct thrombin inhibitor

Boehringer Ingelheim’s Pradaxa has become the first drug in 50 years to be approved in Europe for stroke prevention in …

Takeda and Amylin stop obesity trial

August 8, 2011 Research and Development, Sales and Marketing Amylin, Takeda

Takeda and Amylin have decided to halt further studies of its combination treatment for obesity, due to ‘evolving dynamics’ within …
Pfizer building

Biotica becomes new victim of Pfizer’s R&D downsizing

August 8, 2011 Research and Development, Sales and Marketing

Pfizer has pulled out of a $195 million deal with UK firm Biotica, as it continues to downsize its global …

Meet Wainwright Associates at the TOPRA Symposium and CPhl worldwide

August 7, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates

Wainwright Associates is an independent company offering consultancy services to the pharmaceutical, medical device and healthcare industry in Product Development, …
Gilenya

Gilenya rejected by NICE

August 5, 2011 Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya

NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …

NHS must personalise services for long-term conditions

August 3, 2011 Sales and Marketing NHS, long term conditions

The government is highlighting a scheme in West Yorkshire as providing a way forward for reducing the cost burden on …

Mergers and spending cuts damaging drug research

August 3, 2011 Research and Development, Sales and Marketing LaMattina, Pfizer, research productivity

Big pharma’s policy of mergers and swingeing cuts is having a devastating effect on drug research, says a former Pfizer …
Pfizer HQ

Pfizer looks to spin off animal health and nutrition

August 2, 2011 Sales and Marketing Pfizer, Q2, animal health, divestment, nutrition

Pfizer looks set to spin-off or sell its animal health and nutrition business units in order to focus on human …

US debt deal could hit pharma

August 2, 2011 Sales and Marketing Obama, PhRMA, US, healthcare reform

The deal to raise America’s debt ceiling could have long-term consequences for the US pharma industry. The tense stand-off between …

Teva’s MS treatment disappoints

August 2, 2011 Research and Development, Sales and Marketing Laquinimod, MS, Teva

Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …

Quintiles launches first salesforce in Russia

August 2, 2011 Sales and Marketing CSO, Quintiles, Russia, emerging markets

 Quintiles is set to launch its first contract sales project in Russia with a 40 strong sales team.  The company …
The Gateway to Local Adoption Series

Latest content